Among them, the targeted inhibition of the vascular endothelial growth factor (VEGF) or epidermal growth factor (EGF) signaling pathways has been clinically validated in the treatment of advanced NSCLC [18]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.